The estimated Net Worth of Jayne B. Hart is at least $4.45 Million dollars as of 28 February 2022. Ms Hart owns over 10,500 units of Myriad Genetics stock worth over $4,451,254 and over the last 14 years she sold MYGN stock worth over $0.
Ms has made over 4 trades of the Myriad Genetics stock since 2014, according to the Form 4 filled with the SEC. Most recently she exercised 10,500 units of MYGN stock worth $251,790 on 28 February 2022.
The largest trade she's ever made was exercising 79,000 units of Myriad Genetics stock on 7 April 2014 worth over $1,849,390. On average, Ms trades about 7,741 units every 99 days since 2011. As of 28 February 2022 she still owns at least 169,378 units of Myriad Genetics stock.
You can see the complete history of Ms Hart stock trades at the bottom of the page.
Jayne Baird Hart is the Exec. VP of HR at Myriad Genetics.
Ms Hart is 60, she's been the Exec. VP of HR of Myriad Genetics since . There are 11 older and 14 younger executives at Myriad Genetics. The oldest executive at Myriad Genetics, Inc. is Walter Gilbert, 87, who is the Independent Vice Chairman of the Board.
Jayne's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum, and Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: